Evidence map›Paper›PMID 40438808›Full record

ArticleCureus2025

Managing Levothyroxine Malabsorption in Refractory Hypothyroidism: A Case Report.

Ghada Rashwan, Adil Jumani, Hadiza Ibrahim, Majdi AlNajjar

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ghada RashwanInternal Medicine, Zayed Military Hospital, Abu Dhabi, ARE.
Adil JumaniInternal Medicine, Zayed Military Hospital, Abu Dhabi, ARE.
Hadiza IbrahimInternal Medicine, Zayed Military Hospital, Abu Dhabi, ARE.
Majdi AlNajjarInternal Medicine, Zayed Military Hospital, Abu Dhabi, ARE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Levothyroxine malabsorption is a rare but important cause of refractory hypothyroidism that necessitates alternative therapeutic approaches. We present the case of a 55-year-old woman with long-standing hypothyroidism who continued to experience persistent symptoms despite being on high-dose oral levothyroxine (1500 mcg daily). Laboratory investigations revealed an elevated thyroid-stimulating hormone (TSH) level of 14.160 mIU/L, along with positive anti-gliadin and anti-parietal cell antibodies. A supervised thyroxine (T4) absorption test confirmed true levothyroxine malabsorption. The patient was subsequently transitioned to a liquid levothyroxine formulation at a reduced dose of 600 mcg, which led to significant clinical improvement and normalization of thyroid function. Levothyroxine malabsorption can be attributed to underlying gastrointestinal conditions such as celiac disease and atrophic gastritis. The T4 malabsorption test is a valuable tool in distinguishing true malabsorption from non-adherence or pseudo-malabsorption. In cases of confirmed malabsorption, liquid or parenteral formulations may help improve absorption and lead to better clinical outcomes. This case highlights the importance of identifying thyroid hormone malabsorption in patients with refractory hypothyroidism to ensure optimal management and therapeutic success.

Indexed as

levothyroxine malabsorptionlong levothyroxine absorption test thyroid-stimulating hormone refractory hypothyroidismovert hypothyroidismthyroid disorderthyroid hormone supplements

Identifiers

PMID40438808
PMCPMC12117975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.